http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
-
MEI Pharma and Kyowa Kirin Announce Discontinuation of Zandelisib Development Outside of Japan Following Recent FDA Meeting
-
Kyowa Kirin and MEI Pharma (MEIP) Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin’s Lymphoma in Japan
-
Kyowa Kirin and MEI Pharma Announce Topline Data from the Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-cell non-Hodgkin’s Lymphoma in Japan
-
MEI Pharma and Kyowa Kirin Announce Acceptance of Three Abstracts for Presentation at the American Society of Hematology Annual Meeting 2022
-
MEI Pharma and Kyowa Kirin Announce Publication in The Lancet Oncology of Data from Phase 1b Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-cell Malignancy
-
MEI Pharma and Kyowa Kirin Report Clinical Data on Zandelisib at European Hematology Association 2022 Hybrid Congress
-
MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022
-
MEI Pharma and Kyowa Kirin Announce Acceptance of Abstract for Presentation at the American Society of Clinical Oncology Annual Meeting 2022
-
MEI Pharma and Kyowa Kirin Announce Acceptance of Two Abstracts for Presentation at the European Hematology Association 2022 Hybrid Congress
-
MEI Pharma (MEIP) says FDA informed the companies of its position that a randomized trial is now needed to adequately assess drug efficacy and safety of PI3K inhibitor drug candidates
-
MEI Pharma and Kyowa Kirin Provide Regulatory Update on Zandelisib Following Meeting with the FDA
-
InveniAI and Kyowa Kirin Expand AI-Driven Partnership to a Multi-Year Strategic Collaboration for the Discovery of Novel Targets and Treatments Across Therapeutic Areas
-
MEI Pharma and Kyowa Kirin Announce Data From the Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as a Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma
-
MEI Pharma (MEIP) and Kyowa Kirin receive Orphan Drug Designation for Zandelisib for the Treatment of Follicular Lymphoma
-
MEI Pharma and Kyowa Kirin receive Orphan Drug Designation for Zandelisib for the Treatment of Follicular Lymphoma
-
Amgen And Kyowa Kirin Present Positive Late-Breaking Data From Phase 2 Study Of AMG 451/KHK4083 In Adult Patients With Moderate-to-Severe Atopic Dermatitis At EADV Congress
-
Kyowa Kirin and Amgen Present Positive Late-Breaking Data from Phase 2 Study of KHK4083/AMG 451 in Adult Patients with Moderate-to-Severe Atopic Dermatitis at EADV Congress
-
Amgen To Showcase New Data From Inflammation Portfolio At EADV Virtual Congress 2021
-
MEI Pharma and Kyowa Kirin Announce First Patient Dosed in the Phase 3 COASTAL Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-cell Lymphoma
-
MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program
-
Amgen and Kyowa Kirin to Jointly Develop and Commercialize KHK4083, a Phase 3-Ready, Potential First-In-Class Treatment for Atopic Dermatitis
-
MEI Pharma (MEIP) and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2021
-
MEI Pharma and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2021
-
MEI Pharma (MEIP), Kyowa Kirin to Present Clinical Data from Phase 1b Study of Zandelisib in Combination with Zanubrutinib at the European Hematology Association 2021 Virtual Congress
-
MEI Pharma and Kyowa Kirin to Present Clinical Data from Phase 1b Study of Zandelisib in Combination with Zanubrutinib at the European Hematology Association 2021 Virtual Congress
-
Twist Bioscience and Kyowa Kirin Partner for GPCR Antibody Discovery
-
Ardelyx and Kyowa Kirin Expand Partnership with Two Additional Agreements
-
Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan
-
Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan
-
Kyowa Hakko Kirin and Bristol-Myers Squibb Announce Immuno-Oncology Clinical Collaboration Studying Mogamulizumab and Opdivo (nivolumab) in Advanced Solid Tumors in the U.S.
